We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byMeredith Goodley
Modified over 2 years ago
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program by Marco Ladetto, Chiara Lobetti-Bodoni, Barbara Mantoan, Manuela Ceccarelli, Carola Boccomini, Elisa Genuardi, Annalisa Chiappella, Luca Baldini, Giuseppe Rossi, Alessandro Pulsoni, Francesco Di Raimondo, Luigi Rigacci, Antonello Pinto, Sara Galimberti, Alessia Bari, Delia Rota-Scalabrini, Angela Ferrari, Francesco Zaja, Andrea Gallamini, Giorgina Specchia, Pellegrino Musto, Francesca Gaia Rossi, Enrica Gamba, Andrea Evangelista, and Umberto Vitolo Blood Volume 122(23):3759-3766 November 28, 2013 ©2013 by American Society of Hematology
Study plan for MRD analysis. Marco Ladetto et al. Blood 2013;122:3759-3766 ©2013 by American Society of Hematology
Descriptive results of bcl-2/IgH PCR analysis. Marco Ladetto et al. Blood 2013;122:3759-3766 ©2013 by American Society of Hematology
Time-varying covariate model of accumulation of PCR-negative findings. Marco Ladetto et al. Blood 2013;122:3759-3766 ©2013 by American Society of Hematology
Effect of MRD by response status and treatment group. Marco Ladetto et al. Blood 2013;122:3759-3766 ©2013 by American Society of Hematology
Safety and efficacy of rituximab in patients with hepatitis C virus–related mixed cryoglobulinemia and severe liver disease by Antonio Petrarca, Luigi.
Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk.
CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications by Elias Campo, Steven H. Swerdlow, Nancy L.
Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination by Giulia Benevolo,
How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD by Attilio.
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation.
Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation by Roberto.
New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.
High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma by Jacopo Mariotti, Anna Guidetti, Michele Magni,
Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells by Jonathan M. Irish,
Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.
JAK2V617F mutation for the early diagnosis of Ph − myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis by Francesco Dentali,
Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs) by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large.
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia by Robin Foà, Antonella Vitale,
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,
© 2017 SlidePlayer.com Inc. All rights reserved.